Literature DB >> 12053643

Therapeutic angiogenesis in critical limb and myocardial ischemia.

P R Vale1, J M Isner, K Rosenfield.   

Abstract

Research in animal models of ischemia has shown that administration of angiogenic growth factors, either as a recombinant protein or by gene transfer, can augment nutrient perfusion through neovascularization to promote the development of supplemental collateral blood vessels that will constitute endogenous bypass conduits around occluded native arteries; a strategy termed "therapeutic angiogenesis." In animal models and clinical trials, the best studied cytokines with angiogenic activity are vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). Clinical trials of therapeutic angiogenesis in patients with critical limb ischemia demonstrated resolution of rest pain and/or improved limb integrity, increased pain-free walking time and ankle-brachial index, newly visible collateral vessels by digital subtraction angiography, and qualitative evidence of improved distal flow by magnetic resonance imaging. Initial clinical trials in patients with end-stage coronary artery disease using direct myocardial injection via thoracotomy resulted in large increases in exercise time and marked reductions in anginal symptoms, as well as objective evidence of improved perfusion and left ventricular function. Larger scale placebo-controlled trials have been limited to intracoronary and intravenous administration of recombinant protein, and have not shown significant improvement in exercise time or angina compared to placebo. Larger scale placebo-controlled studies of gene transfer using catheter-based endocardial delivery are in progress. Future clinical studies are required to determine the optimal dose, formulation, route of administration, and combinations of growth factors, as well as the requirement for endothelial progenitor cell or stem cell supplementation, to provide effective and safe therapeutic angiogenesis for patients with critical limb ischemia and chronic myocardial ischemia who are not candidates for conventional revascularization procedures.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12053643     DOI: 10.1111/j.1540-8183.2001.tb00367.x

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  12 in total

1.  Longitudinal in vivo monitoring of rodent glioma models through thinned skull using laser speckle contrast imaging.

Authors:  Abhishek Rege; Alan C Seifert; Dan Schlattman; Yu Ouyang; Khan W Li; Luca Basaldella; Henry Brem; Betty M Tyler; Nitish V Thakor
Journal:  J Biomed Opt       Date:  2012-12       Impact factor: 3.170

2.  CD133+CD34+ stem cells are mobilized after musculoskeletal surgery and target endothelium activated by surgical wound fluid.

Authors:  Maciej Janusz Powerski; Dirk Henrich; Anna Sander; Daniel Wastl; Kendra Ludwig; Ingo Marzi
Journal:  Langenbecks Arch Surg       Date:  2010-03-07       Impact factor: 3.445

3.  Akt1-mediated skeletal muscle growth attenuates cardiac dysfunction and remodeling after experimental myocardial infarction.

Authors:  Satoshi Araki; Yasuhiro Izumiya; Shinsuke Hanatani; Taku Rokutanda; Hiroki Usuku; Yuichi Akasaki; Toru Takeo; Naomi Nakagata; Kenneth Walsh; Hisao Ogawa
Journal:  Circ Heart Fail       Date:  2011-12-01       Impact factor: 8.790

4.  Angiogenesis effect on rat liver after administration of expression vector encoding vascular endothelial growth factor D.

Authors:  Bao-Min Shi; Xiu-Yan Wang; Qing-Ling Mu; Tai-Huang Wu; Hong-Jun Liu; Zhen Yang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

5.  Vascular endothelial growth factor attenuates hepatic sinusoidal capillarization in thioacetamide-induced cirrhotic rats.

Authors:  Hao Xu; Bao-Min Shi; Xiao-Fei Lu; Feng Liang; Xing Jin; Tai-Huang Wu; Jian Xu
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

Review 6.  Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives.

Authors:  Michael G Katz; Anthony S Fargnoli; Andrew P Kendle; Roger J Hajjar; Charles R Bridges
Journal:  Ann Thorac Surg       Date:  2016-01-20       Impact factor: 4.330

7.  Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction.

Authors:  Sara Weis; Satoshi Shintani; Alberto Weber; Rudolf Kirchmair; Malcolm Wood; Adrianna Cravens; Heather McSharry; Atsushi Iwakura; Young-Sup Yoon; Nathan Himes; Deborah Burstein; John Doukas; Richard Soll; Douglas Losordo; David Cheresh
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

8.  Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism.

Authors:  Noriyuki Ouchi; Yuichi Oshima; Koji Ohashi; Akiko Higuchi; Chiaki Ikegami; Yasuhiro Izumiya; Kenneth Walsh
Journal:  J Biol Chem       Date:  2008-08-20       Impact factor: 5.157

Review 9.  Complexity in the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-receptors signaling.

Authors:  Debabrata Mukhopadhyay; Huiyan Zeng; Resham Bhattacharya
Journal:  Mol Cell Biochem       Date:  2004-09       Impact factor: 3.396

10.  Efficient therapy of ischaemic lesions with VEGF121-fibrin in an animal model of systemic sclerosis.

Authors:  Shadab Allipour Birgani; Marion Mailänder; Ines Wasle; Hermann Dietrich; Johann Gruber; Oliver Distler; Roswitha Sgonc
Journal:  Ann Rheum Dis       Date:  2015-09-11       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.